

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

VOLUNTARY ANNOUNCEMENT

INVESTIGATIONAL NEW DRUG APPROVAL FOR LAE102 FOR THE TREATMENT OF OBESITY WAS OBTAINED FROM THE CENTRE FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA

This announcement is made by Laekna, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

Reference is made to the announcements of the Company dated February 29, 2024 and April 15, 2024 in relation to the submission of an Investigational New Drug (the “**IND**”) application to the Centre for Drug Evaluation of the National Medical Products Administration of China (the “**CDE**”) and IND approval obtained from U.S. Food and Drug Administration respectively for LAE102 for the treatment of patients with obesity.

The board (the “**Board**”) of directors of the Company (the “**Directors**”) is pleased to announce that the Group has obtained the IND approval from the CDE for LAE102, an internally discovered monoclonal antibody against ActRIIA, for the treatment of patients with obesity indication.

The Group has commenced to coordinate the clinical study of LAE102 and targets to bring this precision therapy to obesity patients who are in need of novel treatment options.

About LAE102

LAE102 is a monoclonal antibody against ActRIIA, a receptor that plays an important role in muscle regeneration and lipid metabolism. In the pre-clinical models, LAE102 has been shown to increase lean mass and decrease fat mass. In combination with GLP1R agonist, LAE102 can further reduce fat mass and dramatically attenuates lean mass loss induced by GLP1R agonist. This makes LAE102 a drug candidate for achieving quality weight control through reducing fat while keeping muscle mass.

RISK WARNING

LAE102 MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, May 9, 2024

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.